FBXW7 Facilitates Nonhomologous End-Joining via K63-Linked Polyubiquitylation of XRCC4.

Molecular Cell
Qiang ZhangYi Sun

Abstract

FBXW7 is a haploinsufficient tumor suppressor with loss-of-function mutations occurring in human cancers. FBXW7 inactivation causes genomic instability, but the mechanism remains elusive. Here we show that FBXW7 facilitates nonhomologous end-joining (NHEJ) repair and that FBXW7 depletion causes radiosensitization. In response to ionizing radiation, ATM phosphorylates FBXW7 at serine 26 to recruit it to DNA double-strand break (DSB) sites, whereas activated DNA-PKcs phosphorylates XRCC4 at serines 325/326, which promotes binding of XRCC4 to FBXW7. SCF(FBXW7) E3 ligase then promotes polyubiquitylation of XRCC4 at lysine 296 via lysine 63 linkage for enhanced association with the Ku70/80 complex to facilitate NHEJ repair. Consistent with these findings, a small-molecule inhibitor that abrogates XRCC4 polyubiquitylation reduces NHEJ repair. Our study demonstrates one mechanism by which FBXW7 contributes to genome integrity and implies that inactivated FBXW7 in human cancers could be a strategy for increasing the efficacy of radiotherapy.

References

Aug 1, 1997·Current Biology : CB·S E CritchlowS P Jackson
Oct 29, 1999·Genes & Development·A J PierceM Jasin
May 24, 2000·Proceedings of the National Academy of Sciences of the United States of America·D O FergusonF W Alt
Mar 5, 2003·The Journal of Experimental Medicine·Sean RooneyJoAnn Sekiguchi
Mar 6, 2004·Nature·Harith RajagopalanChristoph Lengauer
Nov 3, 2004·Genes & Development·Jianping JinJ Wade Harper
Jan 18, 2006·Biochemical and Biophysical Research Communications·Rebecca E FosterKaren M Frank
Apr 25, 2006·Nature Reviews. Cancer·Keiichi I Nakayama, Keiko Nakayama
Nov 25, 2006·Proceedings of the National Academy of Sciences of the United States of America·Pierre-Olivier MariDik C van Gent
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Shan ZhaGang Li
Oct 3, 2007·Cancer Research·Shahab AkhoondiCharles Spruck
Jun 19, 2008·The Journal of Cell Biology·Jonathan E GrimBruce E Clurman
Feb 17, 2009·Molecular Cell·Zhijian J Chen, Lijun J Sun
Jun 6, 2009·Annual Review of Biochemistry·Raymond J Deshaies, Claudio A P Joazeiro
Jun 17, 2010·Nature Reviews. Molecular Cell Biology·Helle D Ulrich, Helen Walden
Oct 12, 2010·Journal of Nucleic Acids·Sheetal Sharma, Sathees C Raghavan
Jan 21, 2011·Current Cancer Drug Targets·L Jia, Y Sun
Jul 9, 2011·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Penny A JeggoMarkus Löbrich
Jul 18, 2012·Expert Opinion on Investigational Drugs·Steffan T NawrockiJennifer S Carew
Nov 16, 2012·Current Pharmaceutical Design·Yongchao Zhao, Yi Sun
May 3, 2013·Cold Spring Harbor Perspectives in Biology·Kishore K ChiruvellaThomas E Wilson
Jul 13, 2013·Frontiers in Genetics·Cristina Bartocci, Eros Lazzerini Denchi
Jul 31, 2013·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Jan TheysMarc Vooijs
Dec 24, 2013·The British Journal of Radiology·A Kakarougkas, P A Jeggo
Jan 15, 2014·Antioxidants & Redox Signaling·Yongchao ZhaoYi Sun
Mar 4, 2014·DNA Repair·Sarvan Kumar RadhakrishnanSusan P Lees-Miller
Mar 25, 2014·Nature Reviews. Cancer·Zhiwei WangWenyi Wei

❮ Previous
Next ❯

Citations

Aug 28, 2016·Nucleic Acids Research·Xuehui HongSharon R Pine
Oct 21, 2016·Oncoimmunology·Erika VacchelliLorenzo Galluzzi
Oct 21, 2016·Neoplasia : an International Journal for Oncology Research·Qiang ZhangMeredith A Morgan
Sep 21, 2016·The Journal of Veterinary Medical Science·Manabu KoikeAki Koike
Jan 31, 2017·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Stuart L Rulten, Gabrielle J Grundy
Oct 27, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Hidetaka AritaHideki Nakayama
Dec 16, 2017·Nature Reviews. Cancer·Daniela SenftZe'ev A Ronai
Apr 25, 2019·American Journal of Physiology. Renal Physiology·Shi-Jing MoBang-Chuan Hu
Jun 4, 2019·Proceedings of the National Academy of Sciences of the United States of America·Huiyin LanYi Sun
Jun 18, 2020·Cancers·Marcus WurlitzerThorsten Rieckmann
May 12, 2020·Molecular & Cellular Oncology·Jason K DouglasHarry J Wasvary
Apr 30, 2017·Nucleic Acids Research·R Daniel AceytunoJ N Mark Glover
Jan 22, 2020·The Journal of Clinical Investigation·Benjamin C ChandlerCorey Speers
Jul 15, 2020·Nature Microbiology·Christin HerrmannMatthew D Weitzman
Aug 9, 2018·Molecular Cancer·Chien-Hung YehChristophe Nicot
Oct 22, 2019·Frontiers in Physiology·Shahd FouadVincenzo D'Angiolella
Jul 26, 2019·Protein & Cell·Huiyin Lan, Yi Sun
Jun 24, 2020·Cancers·Barbara N BorsosTibor Pankotai
Apr 25, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Joseph J CaumannsSteven de Jong
Mar 10, 2019·Progress in Biophysics and Molecular Biology·Philippe FritPatrick Calsou
Apr 13, 2021·Journal of Radiation Research·Anie Day D C AsaYoshihisa Matsumoto
Feb 8, 2020·Journal of the Neurological Sciences·Shiming LiuHaowen Wang
Aug 5, 2021·Molecular Carcinogenesis·Xiao HuYue Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Ataxia telangiectasia

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

© 2022 Meta ULC. All rights reserved